These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39096658)

  • 1. Integrated machine learning screened glutamine metabolism-associated biomarker SLC1A5 to predict immunotherapy response in hepatocellular carcinoma.
    Zhang G; Xiao Y; Liu H; Wu Y; Xue M; Li J
    Immunobiology; 2024 Sep; 229(5):152841. PubMed ID: 39096658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Zhang G; Xiao Y; Tan J; Liu H; Fan W; Li J
    J Transl Med; 2024 Jun; 22(1):543. PubMed ID: 38844930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA
    Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
    Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identify an innovative ferroptosis-related gene in hepatocellular carcinoma.
    Hu G; Huang X; Zhang B; Gao P; Wu W; Wang J
    J Clin Lab Anal; 2022 Sep; 36(9):e24632. PubMed ID: 35908779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
    J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.
    Lu J; Yu C; Bao Q; Zhang X; Wang J
    Front Immunol; 2022; 13():973649. PubMed ID: 36081504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.
    Tambay V; Raymond VA; Voisin L; Meloche S; Bilodeau M
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
    Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
    Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
    Pan Y; Han M; Zhang X; He Y; Yuan C; Xiong Y; Li X; Zeng C; Lu K; Zhu H; Lu X; Liu Q; Liang H; Liao Z; Ding Z; Zhang Z; Chen X; Zhang W; Zhang B
    Cell Oncol (Dordr); 2022 Feb; 45(1):163-178. PubMed ID: 35089546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma.
    Zhang X; Zheng P; Meng B; Zhuang H; Lu B; Yao J; Han F; Luo S
    Clin Exp Med; 2024 Jun; 24(1):129. PubMed ID: 38884870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
    Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
    Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.
    Cao L; Liu M; Ma X; Rong P; Zhang J; Wang W
    Curr Med Chem; 2024; 31(17):2414-2430. PubMed ID: 37936457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
    Liu Z; Yang L; Liu C; Wang Z; Xu W; Lu J; Wang C; Xu X
    Front Immunol; 2024; 15():1371829. PubMed ID: 38933262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment.
    Wei S; Tan J; Huang X; Zhuang K; Qiu W; Chen M; Ye X; Wu M
    J Transl Med; 2024 Jul; 22(1):711. PubMed ID: 39085893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
    Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
    Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
    Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ratio of resident to exhausted CD4 + T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma.
    Zuo A; Lv J; Jia W; Ba Y; Liu S; Zhang Y; Weng S; Xu H; Liu L; Wang L; Han X; Liu Z
    BMC Cancer; 2024 Sep; 24(1):1152. PubMed ID: 39289669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma.
    Xu KQ; Gong Z; Yang JL; Xia CQ; Zhao JY; Chen X
    World J Gastroenterol; 2024 Sep; 30(34):3894-3925. PubMed ID: 39350784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.